NetworkNewsBreaks – Brain Scientific Inc. (BRSF)
Post# of 129
(Total Views: 236)
Posted On: 07/14/2021 4:18:39 PM
NetworkNewsBreaks – Brain Scientific Inc. (BRSF) Collaborating to Further Research in Psychedelic Treatment for Mental Health
Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has partnered with Ehave Inc., a provider of digital therapeutics for the psychedelic and mental health sectors. The partnership is intended to change the fact that although there are currently 250 identified biochemical markers about a broad range of the body’s organic system and how they function, the approach to utilize them to improve diagnostic accuracy and patient outcomes remains challenging for psychiatric disorders. Additionally, experts caution that even though a potential breakthrough has been found pertaining to treating a range of mental illnesses, which could have profound implications for a space that has seen few pharmacological advancements over recent decades, more research is needed. “This is where the partnership between Brain Scientific and Ehave can potentially make a difference,” reads a recent article. “The two companies signed the MoU defining a collaboration framework that will allow them to exploit graph-based AI linked data protocols to develop neural net algorithms.” The collaborators will use the data and algorithms to “statistically correlate biomarkers for the identification of psychedelic drug administration as a treatment for neurological disorders such as chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD, and schizophrenia.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has partnered with Ehave Inc., a provider of digital therapeutics for the psychedelic and mental health sectors. The partnership is intended to change the fact that although there are currently 250 identified biochemical markers about a broad range of the body’s organic system and how they function, the approach to utilize them to improve diagnostic accuracy and patient outcomes remains challenging for psychiatric disorders. Additionally, experts caution that even though a potential breakthrough has been found pertaining to treating a range of mental illnesses, which could have profound implications for a space that has seen few pharmacological advancements over recent decades, more research is needed. “This is where the partnership between Brain Scientific and Ehave can potentially make a difference,” reads a recent article. “The two companies signed the MoU defining a collaboration framework that will allow them to exploit graph-based AI linked data protocols to develop neural net algorithms.” The collaborators will use the data and algorithms to “statistically correlate biomarkers for the identification of psychedelic drug administration as a treatment for neurological disorders such as chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD, and schizophrenia.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)